Value the standardized treatment of pediatric retinal diseases to improve its treatment level_Chinese Journal of Ocular Fundus Diseases

Authors：

 Zhang Guoming , Zhao Jinfeng

Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen Key Medical Discipline, Guangdong High-level Clinical Key Discipline, Shenzhen 518040, China;

Corresponding?author：

Zhang Guoming, Email: zhang-guoming@163.com

Keywords：

Retinal Diseases/therapy; Child; Benchmarking; Editorial

DOI：

10.3760/cma.j.cn511434-20200806-00380

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, with the deepening of understanding of children's retinal diseases and the continuous updating of treatment techniques, the efficacy of children's retinal diseases has also been improved. Due to the particularity of the anatomical structure of the retina of children in the growth and development stage and the pathogenesis, clinical manifestations and outcomes of children's retinal diseases are different from those of adults, the principles of treatment of adult retinal diseases cannot be directly applied to children's retinal diseases. Cryotherapy, laser photocoagulation, intravitreal injection of anti-VEGF drugs, and vitreoretinal surgery are the main treatment methods for children's retinal diseases. However, there are still many problems in the selection of indications, equipment parameters, and treatment of complications. The treatment norms of the disease need to be further improved. Therefore, research on the treatment of children's retinal diseases, and the establishment of surgical standards and norms through expert consensus and other methods are helpful for the treatment of children's retinal diseases.

Citation： Zhang Guoming, Zhao Jinfeng. Value the standardized treatment of pediatric retinal diseases to improve its treatment level. Chinese Journal of Ocular Fundus Diseases, 2020, 36(8): 583-589. doi: 10.3760/cma.j.cn511434-20200806-00380 Copy

1.	趙培泉, 張琦, 許宇. 提高小兒視網膜疾病的認知水平, 推動我國小兒視網膜疾病研究的深入開展[J]. 中華眼底病雜志, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.Zhao PQ, Zhang Q, Xu Y. The diagnosis and treatment of pediatric retinal disease[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.
2.	張國明, 曾鍵. 深入研究兒童適宜眼底影像檢查技術, 努力提高小兒視網膜疾病診斷水平[J]. 中華眼底病雜志, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.Zhang GM, Zeng J. Study pediatric fundus imaging techniques to improve the diagnosis of retinal diseases in children[J]. Chin J Ocul Fundus Dis, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.
3.	Zhao J, Wu Z, Lam W, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity[J/OL]. Br J Ophthalmol, 2020, 2020: E1[2020-02-12]. https://bjo.bmj.com/content/early/2020/02/12/bjophthalmol-2019-315520.long. DOI: 10.1136/bjophthalmol-2019-315520. [publishedonline ahead of print].
4.	中華醫學會眼科學分會眼底病學組. 中國早產兒視網膜病變篩查指南(2014年)[J]. 中華眼科雜志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Chinese Ocular Fundus Diseases Society, Chinese Ophthalmological Society, Chinese Medical Association. Guidelines for screening retinopathy of premature infants in China(2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
5.	趙培泉, 單海冬, 程朝暉, 等. 閾值前病變1型和閾值期早產兒視網膜病變的激光和冷凍治療[J]. 中華眼底病雜志, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.Zhao PQ, Shan HD, Cheng CH, et al. Photocoagulation and cryotherapy for prethreshold type 1 and threshold disease of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.
6.	彭婕, 張琦, 龍新純, 等. 色素失禁癥的眼部表現及治療[J]. 中華眼底病雜志, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.Peng J, Zhang Q, Long XC, et al. Ocular manifestations and treatment of pigment incontinence[J]. Chin J Ocul Fundus Dis, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.
7.	吳中耀, 楊華勝, 陳智聰, 等. 視網膜母細胞瘤的激光、冷凍和放射治療[J]. 中華眼底病雜志, 1996, 12(1): 48-50, 82.Wu ZY, Yang HS, Chen ZC, et al. Laser, cryotherapy and radiotherapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 1996, 12(1): 48-50, 82.
8.	張國明, 曾鍵, 黃麗娜, 等. 廣角數碼兒童視網膜成像系統引導下激光光凝治療早產兒視網膜病變[J]. 中華眼底病雜志, 2008, 24(1): 17-19.Zhang GM, Zeng J, Huang LN, et al. Wide-field digital pediatric retinal imaging system-assisted photocoagulation for retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2008, 24(1): 17-19.
9.	趙琦, 彭曉燕, 張永鵬, 等. 視網膜冷凍手術聯合玻璃體注射曲安奈德治療伴有滲出性視網膜脫離Coats病的初步觀察[J]. 中華眼底病雜志, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.Zhao Q, Peng XY, Zhang YP, et al. Using cryotherapy and intravitreal triamcinolone injection to treat Coats' disease with exudative retinal detachment[J]. Chin J Ocul Fundus Dis, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.
10.	Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial[J]. JAMA Ophthalmol, 2014, 132(11): 1327-1333. DOI: 10.1001/jamaophthalmol.2014.2772.
11.	Sanghi G, Dogra MR, Das P, et al. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment[J]. Retina, 2009, 29(9): 1335-1339. DOI: 10.1097/IAE.0b013e3181a68f3a.
12.	Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
13.	張國明, 唐松, 曾鍵, 等. 早產兒視網膜病變激光光凝輔助玻璃體腔注射抗血管內皮生長因子單克隆抗體bevacizumab治療臨床療效觀察[J]. 中華眼底病雜志, 2012, 28(1): 18-21.Zhang GM, Tang S, Zeng J, et al. The clinical observation of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2012, 28(1): 18-21.
14.	Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone Ⅱ treatment-requiring retinopathy of prematurity[J]. Retina, 2017, 37(4): 710-717. DOI: 10.1097/IAE.0000000000001241.
15.	費萍, 張琦, 許宇, 等. 兒童牽牛花綜合征并發視網膜脫離的臨床特征及治療效果觀察[J]. 中華眼底病雜志, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.Fei P, Zhang Q, Xu Y, et al. Clinical analysis and management of pediatric retinal detachment associated with morning glory syndrome[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.
16.	趙培泉, 虞瑛青, 單海冬, 等. 家族性滲出性玻璃體視網膜病變治療觀察[J]. 中華眼底病雜志, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.Zhao PQ, Yu YQ, Shan HD, et al. Treatment for familial exudative vitreoretinopathy[J]. Chin J Ocul Fundus Dis, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.
17.	Shaikh S, Trese MT, Archer SM. Fluorescein angiographic findings in incontinentia pigmenti[J]. Retina, 2004, 24(4): 628-629. DOI: 10.1097/00006982-200408000-00025.
18.	Rishi P, Singh N, Rishi E. Retinopathy in incontinentia pigmenti[J]. Indian J Ophthalmol, 2019, 67(6): 940-942. DOI: 10.4103/ijo.IJO_760_18.
19.	Chen CJ, Han IC, Tian J, et al. Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti: analysis of peripheral vascular changes and incidence of retinal detachment[J]. JAMA Ophthalmol, 2015, 133(5): 542-548. DOI: 10.1001/jamaophthalmol.2015.22.
20.	Ni Y, Huang X, Ruan L, et al. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti[J]. J AAPOS, 2018, 22(4): 325-327. DOI: 10.1016/j.jaapos.2018.01.008.
21.	Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China[J]. Ophthalmology, 2017, 124(3): 408-409. DOI: 10.1016/j.ophtha.2016.10.032.
22.	Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone Ⅱ, stage 3 with plus disease[J]. BMC Ophthalmol, 2015, 15: 20. DOI: 10.1186/s12886-015-0001-7.
23.	VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
24.	Ho M, Yip WWK, Chan VCK, et al. Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child[J]. Retin Cases Brief Rep, 2017, 11(4): 352-355. DOI: 10.1097/ICB.0000000000000369.
25.	Lu YZ, Deng GD, Liu JH, et al. The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater[J]. Int J Ophthalmol, 2018, 11(6): 976-980. DOI: 10.18240/ijo.2018.06.13.
26.	姜華, 方倩, 鄧海浪, 等. 經眼動脈灌注化學藥物治療視網膜母細胞瘤臨床療效觀察[J]. 中華眼底病雜志, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.Jiang H, Fang Q, Deng HL, et al. Intra-arterial chemotherapy as secondly therapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.
27.	侯憲如, 程湧, 張琦, 等. 玻璃體腔注射卡鉑聯合貝伐單抗治療難治型視網膜母細胞瘤的療效觀察[J]. 中華眼科雜志, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.Hou XR, Cheng Y, Zhang Q, et al. Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma[J]. Chin J Ophthalmol, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.
28.	Gan NY, Lam WC. Special considerations for pediatric vitreoretinal surgery[J]. Taiwan J Ophthalmol, 2018, 8(4): 237-242. DOI: 10.4103/tjo.tjo_83_18.
29.	Ling KP, Wu AL, Lai CC, et al. Short-term postoperative perfluoro-n-octane tamponade for pediatric recurrent retinal detachment[J]. Taiwan J Ophthalmol, 2018, 8(4): 249-252. DOI: 10.4103/tjo.tjo_100_18.
30.	Dyrda A, Català-Mora J, Rey A, et al. Macular hole after poppers (Alkyl Nitrate) inhalation in a child[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(11): 897-900. DOI: 10.3928/23258160-20181101-12.
31.	Savla LP, Nene A, Sutar S, et al. Spontaneous attachment of rhegmatogenous retinal detachment following vitrectomy for stage 4B retinopathy of prematurity and atypical retinal changes post-resolution[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(7): 544-547. DOI: 10.3928/23258160-20180628-13.
32.	Wood EH, Drenser KA, Capone A Jr. Diagnosis and management of familial exudative vitreoretinopathy: a lifelong, progressive, and often asymmetric disease[J/OL]. JAMA Ophthalmol, 2019, 2019: E1[2019-06-06]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2019.1484. DOI: 10.1001/jamaophthalmol.2019.1484. [publishedonline head of print].
33.	Liu J, Zhao P. Lamellar macular hole with lamellar hole-associated epiretinal proliferation in familial exudative vitreoretinopathy[J/OL]. Retin Cases Brief Rep, 2018, 2018: E1[2018-08-21]. https://doi.org/10.1097/ICB.0000000000000807. DOI: 10.1097/ICB.0000000000000807. [publishedonline ahead of print].
34.	Yeo DCM, Nagiel A, Yang U, et al. Endoscopy for pediatric retinal disease[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 200-207. DOI: 10.22608/APO.2018154.
35.	Wong SC, Lee TC, Heier JS, et al. Endoscopic vitrectomy[J]. Curr Opin Ophthalmol, 2014, 25(3): 195-206. DOI: 10.1097/ICU.0000000000000052.
36.	Yousef YA, Manna M, Khalil MB, et al. Surgical repair of rhegmatogenous retinal detachment in eyes harboring active retinoblastoma[J]. Ophthalmic Genet, 2016, 37(3): 314-317. DOI: 10.3109/13816810.2015.1046556.
37.	姜燕榮, 黎曉新, 殷春悅. 兒童孔源性視網膜脫離手術治療特點及療效分析[J]. 中華眼科雜志, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.Jiang YR, Li XX, Yin CY. Evaluation of treatment for retinal detachment in juveniles[J]. Chin J Ophthalmol, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.
38.	Papakostas TD, Vavvas D. Postoperative complications of scleral buckling[J]. Semin Ophthalmol, 2018, 33(1): 70-74. DOI: 10.1080/08820538.2017.1353816.
39.	Reddy MA, Naeem Z, Duncan C, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma[J]. Br J Ophthalmol, 2017, 101(12): 1704-1708. DOI: 10.1136/bjophthalmol-2017-310294.
40.	Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds[J]. Br J Ophthalmol, 2019, 103(4): 488-493. DOI: 10.1136/bjophthalmol-2018-312037.
41.	高翔, 王海燕, 王雨生. 復發或頑固性眼內視網膜母細胞瘤玻璃體腔化學藥物治療的現狀與進展[J]. 中華眼底病雜志, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.Gao X, Wang HY, Wang YS. The status and progress of intravitreal chemotherapy for resistant or recurrent retinoblastoma[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.
42.	魏文斌, 周楠. 重視視網膜母細胞瘤的規范化治療, 提升視網膜母細胞瘤的治療水平[J]. 中華眼底病雜志, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.Wei WB, Zhou N. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.
43.	DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina[J]. J Clin Invest, 2018, 128(6): 2177-2188. DOI: 10.1172/JCI120429.
44.	杜洋, 蘇冠方. 家族性滲出性玻璃體視網膜病變致病基因研究進展[J]. 眼科新進展, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.Du Y, Su GF. Recent advances in pathogenic genes of familial exudative vitreoretinopathy[J]. Rec Adv Ophthalmol, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.
45.	Hassall MM, Barnard AR, MacLaren RE. Gene therapy for color blindness[J]. Yale J Biol Med, 2017, 90(4): 543-551.
46.	Lu LJ, Liu J, Adelman RA. Novel therapeutics for stargardt disease[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1057-1062. DOI: 10.1007/s00417-017-3619-8.
47.	Parker MA, Choi D, Erker LR, et al. Test-retest variability of functional and structural parameters in patients with stargardt disease participating in the SAR422459 gene therapy trial[J]. Transl Vis Sci Technol, 2016, 5(5): 10. DOI: 10.1167/tvst.5.5.10.
48.	Fischer MD, Michalakis S, Wilhelm B, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial[J]. JAMA Ophthalmol, 2020, 138(6): 1-9. DOI: 10.1001/jamaophthalmol.2020.1032.
49.	Bhattacharya S, Gangaraju R, Chaum E. Recent advances in retinal stem cell therapy[J]. Curr Mol Biol Rep, 2017, 3(3): 172-182. DOI: 10.1007/s40610-017-0069-3.
50.	Bashar AE, Metcalfe AL, Viringipurampeer IA, et al. An ex vivo gene therapy approach in X-linked retinoschisis[J]. Mol Vis, 2016, 22: 718-733.
51.	Ma QQ, Liu FY, Shi M, et al. Bone marrow mesenchymal stem cells modified by angiogenin-1 promotes tissue repair in mice with oxygen-induced retinopathy of prematurity by promoting retinal stem cell proliferation and differentiation[J]. J Cell Physiol, 2019, 234(11): 21027-21038. DOI: 10.1002/jcp.28706.
52.	韓如意, 金子兵. 遺傳性眼底病基因和干細胞治療趨勢與面臨的挑戰和機遇[J]. 中華眼底病雜志, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.Han RY, Jin ZB. Progress and opportunities of gene and stem cell therapy on hereditary ocular fundus diseases[J]. Chin J Ocul Fundus Dis, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.
53.	Xu Y, Lu X, Hu Y, et al. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice[J/OL]. J Pineal Res, 2018, 64(4): 12473[2018-03-08]. https://doi.org/10.1111/jpi.12473. DOI: 10.1111/jpi.12473.

1. 趙培泉, 張琦, 許宇. 提高小兒視網膜疾病的認知水平, 推動我國小兒視網膜疾病研究的深入開展[J]. 中華眼底病雜志, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.Zhao PQ, Zhang Q, Xu Y. The diagnosis and treatment of pediatric retinal disease[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.
2. 張國明, 曾鍵. 深入研究兒童適宜眼底影像檢查技術, 努力提高小兒視網膜疾病診斷水平[J]. 中華眼底病雜志, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.Zhang GM, Zeng J. Study pediatric fundus imaging techniques to improve the diagnosis of retinal diseases in children[J]. Chin J Ocul Fundus Dis, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.
3. Zhao J, Wu Z, Lam W, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity[J/OL]. Br J Ophthalmol, 2020, 2020: E1[2020-02-12]. https://bjo.bmj.com/content/early/2020/02/12/bjophthalmol-2019-315520.long. DOI: 10.1136/bjophthalmol-2019-315520. [publishedonline ahead of print].
4. 中華醫學會眼科學分會眼底病學組. 中國早產兒視網膜病變篩查指南(2014年)[J]. 中華眼科雜志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Chinese Ocular Fundus Diseases Society, Chinese Ophthalmological Society, Chinese Medical Association. Guidelines for screening retinopathy of premature infants in China(2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
5. 趙培泉, 單海冬, 程朝暉, 等. 閾值前病變1型和閾值期早產兒視網膜病變的激光和冷凍治療[J]. 中華眼底病雜志, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.Zhao PQ, Shan HD, Cheng CH, et al. Photocoagulation and cryotherapy for prethreshold type 1 and threshold disease of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.
6. 彭婕, 張琦, 龍新純, 等. 色素失禁癥的眼部表現及治療[J]. 中華眼底病雜志, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.Peng J, Zhang Q, Long XC, et al. Ocular manifestations and treatment of pigment incontinence[J]. Chin J Ocul Fundus Dis, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.
7. 吳中耀, 楊華勝, 陳智聰, 等. 視網膜母細胞瘤的激光、冷凍和放射治療[J]. 中華眼底病雜志, 1996, 12(1): 48-50, 82.Wu ZY, Yang HS, Chen ZC, et al. Laser, cryotherapy and radiotherapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 1996, 12(1): 48-50, 82.
8. 張國明, 曾鍵, 黃麗娜, 等. 廣角數碼兒童視網膜成像系統引導下激光光凝治療早產兒視網膜病變[J]. 中華眼底病雜志, 2008, 24(1): 17-19.Zhang GM, Zeng J, Huang LN, et al. Wide-field digital pediatric retinal imaging system-assisted photocoagulation for retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2008, 24(1): 17-19.
9. 趙琦, 彭曉燕, 張永鵬, 等. 視網膜冷凍手術聯合玻璃體注射曲安奈德治療伴有滲出性視網膜脫離Coats病的初步觀察[J]. 中華眼底病雜志, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.Zhao Q, Peng XY, Zhang YP, et al. Using cryotherapy and intravitreal triamcinolone injection to treat Coats' disease with exudative retinal detachment[J]. Chin J Ocul Fundus Dis, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.
10. Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial[J]. JAMA Ophthalmol, 2014, 132(11): 1327-1333. DOI: 10.1001/jamaophthalmol.2014.2772.
11. Sanghi G, Dogra MR, Das P, et al. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment[J]. Retina, 2009, 29(9): 1335-1339. DOI: 10.1097/IAE.0b013e3181a68f3a.
12. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
13. 張國明, 唐松, 曾鍵, 等. 早產兒視網膜病變激光光凝輔助玻璃體腔注射抗血管內皮生長因子單克隆抗體bevacizumab治療臨床療效觀察[J]. 中華眼底病雜志, 2012, 28(1): 18-21.Zhang GM, Tang S, Zeng J, et al. The clinical observation of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2012, 28(1): 18-21.
14. Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone Ⅱ treatment-requiring retinopathy of prematurity[J]. Retina, 2017, 37(4): 710-717. DOI: 10.1097/IAE.0000000000001241.
15. 費萍, 張琦, 許宇, 等. 兒童牽牛花綜合征并發視網膜脫離的臨床特征及治療效果觀察[J]. 中華眼底病雜志, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.Fei P, Zhang Q, Xu Y, et al. Clinical analysis and management of pediatric retinal detachment associated with morning glory syndrome[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.
16. 趙培泉, 虞瑛青, 單海冬, 等. 家族性滲出性玻璃體視網膜病變治療觀察[J]. 中華眼底病雜志, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.Zhao PQ, Yu YQ, Shan HD, et al. Treatment for familial exudative vitreoretinopathy[J]. Chin J Ocul Fundus Dis, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.
17. Shaikh S, Trese MT, Archer SM. Fluorescein angiographic findings in incontinentia pigmenti[J]. Retina, 2004, 24(4): 628-629. DOI: 10.1097/00006982-200408000-00025.
18. Rishi P, Singh N, Rishi E. Retinopathy in incontinentia pigmenti[J]. Indian J Ophthalmol, 2019, 67(6): 940-942. DOI: 10.4103/ijo.IJO_760_18.
19. Chen CJ, Han IC, Tian J, et al. Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti: analysis of peripheral vascular changes and incidence of retinal detachment[J]. JAMA Ophthalmol, 2015, 133(5): 542-548. DOI: 10.1001/jamaophthalmol.2015.22.
20. Ni Y, Huang X, Ruan L, et al. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti[J]. J AAPOS, 2018, 22(4): 325-327. DOI: 10.1016/j.jaapos.2018.01.008.
21. Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China[J]. Ophthalmology, 2017, 124(3): 408-409. DOI: 10.1016/j.ophtha.2016.10.032.
22. Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone Ⅱ, stage 3 with plus disease[J]. BMC Ophthalmol, 2015, 15: 20. DOI: 10.1186/s12886-015-0001-7.
23. VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
24. Ho M, Yip WWK, Chan VCK, et al. Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child[J]. Retin Cases Brief Rep, 2017, 11(4): 352-355. DOI: 10.1097/ICB.0000000000000369.
25. Lu YZ, Deng GD, Liu JH, et al. The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater[J]. Int J Ophthalmol, 2018, 11(6): 976-980. DOI: 10.18240/ijo.2018.06.13.
26. 姜華, 方倩, 鄧海浪, 等. 經眼動脈灌注化學藥物治療視網膜母細胞瘤臨床療效觀察[J]. 中華眼底病雜志, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.Jiang H, Fang Q, Deng HL, et al. Intra-arterial chemotherapy as secondly therapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.
27. 侯憲如, 程湧, 張琦, 等. 玻璃體腔注射卡鉑聯合貝伐單抗治療難治型視網膜母細胞瘤的療效觀察[J]. 中華眼科雜志, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.Hou XR, Cheng Y, Zhang Q, et al. Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma[J]. Chin J Ophthalmol, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.
28. Gan NY, Lam WC. Special considerations for pediatric vitreoretinal surgery[J]. Taiwan J Ophthalmol, 2018, 8(4): 237-242. DOI: 10.4103/tjo.tjo_83_18.
29. Ling KP, Wu AL, Lai CC, et al. Short-term postoperative perfluoro-n-octane tamponade for pediatric recurrent retinal detachment[J]. Taiwan J Ophthalmol, 2018, 8(4): 249-252. DOI: 10.4103/tjo.tjo_100_18.
30. Dyrda A, Català-Mora J, Rey A, et al. Macular hole after poppers (Alkyl Nitrate) inhalation in a child[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(11): 897-900. DOI: 10.3928/23258160-20181101-12.
31. Savla LP, Nene A, Sutar S, et al. Spontaneous attachment of rhegmatogenous retinal detachment following vitrectomy for stage 4B retinopathy of prematurity and atypical retinal changes post-resolution[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(7): 544-547. DOI: 10.3928/23258160-20180628-13.
32. Wood EH, Drenser KA, Capone A Jr. Diagnosis and management of familial exudative vitreoretinopathy: a lifelong, progressive, and often asymmetric disease[J/OL]. JAMA Ophthalmol, 2019, 2019: E1[2019-06-06]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2019.1484. DOI: 10.1001/jamaophthalmol.2019.1484. [publishedonline head of print].
33. Liu J, Zhao P. Lamellar macular hole with lamellar hole-associated epiretinal proliferation in familial exudative vitreoretinopathy[J/OL]. Retin Cases Brief Rep, 2018, 2018: E1[2018-08-21]. https://doi.org/10.1097/ICB.0000000000000807. DOI: 10.1097/ICB.0000000000000807. [publishedonline ahead of print].
34. Yeo DCM, Nagiel A, Yang U, et al. Endoscopy for pediatric retinal disease[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 200-207. DOI: 10.22608/APO.2018154.
35. Wong SC, Lee TC, Heier JS, et al. Endoscopic vitrectomy[J]. Curr Opin Ophthalmol, 2014, 25(3): 195-206. DOI: 10.1097/ICU.0000000000000052.
36. Yousef YA, Manna M, Khalil MB, et al. Surgical repair of rhegmatogenous retinal detachment in eyes harboring active retinoblastoma[J]. Ophthalmic Genet, 2016, 37(3): 314-317. DOI: 10.3109/13816810.2015.1046556.
37. 姜燕榮, 黎曉新, 殷春悅. 兒童孔源性視網膜脫離手術治療特點及療效分析[J]. 中華眼科雜志, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.Jiang YR, Li XX, Yin CY. Evaluation of treatment for retinal detachment in juveniles[J]. Chin J Ophthalmol, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.
38. Papakostas TD, Vavvas D. Postoperative complications of scleral buckling[J]. Semin Ophthalmol, 2018, 33(1): 70-74. DOI: 10.1080/08820538.2017.1353816.
39. Reddy MA, Naeem Z, Duncan C, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma[J]. Br J Ophthalmol, 2017, 101(12): 1704-1708. DOI: 10.1136/bjophthalmol-2017-310294.
40. Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds[J]. Br J Ophthalmol, 2019, 103(4): 488-493. DOI: 10.1136/bjophthalmol-2018-312037.
41. 高翔, 王海燕, 王雨生. 復發或頑固性眼內視網膜母細胞瘤玻璃體腔化學藥物治療的現狀與進展[J]. 中華眼底病雜志, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.Gao X, Wang HY, Wang YS. The status and progress of intravitreal chemotherapy for resistant or recurrent retinoblastoma[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.
42. 魏文斌, 周楠. 重視視網膜母細胞瘤的規范化治療, 提升視網膜母細胞瘤的治療水平[J]. 中華眼底病雜志, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.Wei WB, Zhou N. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.
43. DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina[J]. J Clin Invest, 2018, 128(6): 2177-2188. DOI: 10.1172/JCI120429.
44. 杜洋, 蘇冠方. 家族性滲出性玻璃體視網膜病變致病基因研究進展[J]. 眼科新進展, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.Du Y, Su GF. Recent advances in pathogenic genes of familial exudative vitreoretinopathy[J]. Rec Adv Ophthalmol, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.
45. Hassall MM, Barnard AR, MacLaren RE. Gene therapy for color blindness[J]. Yale J Biol Med, 2017, 90(4): 543-551.
46. Lu LJ, Liu J, Adelman RA. Novel therapeutics for stargardt disease[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1057-1062. DOI: 10.1007/s00417-017-3619-8.
47. Parker MA, Choi D, Erker LR, et al. Test-retest variability of functional and structural parameters in patients with stargardt disease participating in the SAR422459 gene therapy trial[J]. Transl Vis Sci Technol, 2016, 5(5): 10. DOI: 10.1167/tvst.5.5.10.
48. Fischer MD, Michalakis S, Wilhelm B, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial[J]. JAMA Ophthalmol, 2020, 138(6): 1-9. DOI: 10.1001/jamaophthalmol.2020.1032.
49. Bhattacharya S, Gangaraju R, Chaum E. Recent advances in retinal stem cell therapy[J]. Curr Mol Biol Rep, 2017, 3(3): 172-182. DOI: 10.1007/s40610-017-0069-3.
50. Bashar AE, Metcalfe AL, Viringipurampeer IA, et al. An ex vivo gene therapy approach in X-linked retinoschisis[J]. Mol Vis, 2016, 22: 718-733.
51. Ma QQ, Liu FY, Shi M, et al. Bone marrow mesenchymal stem cells modified by angiogenin-1 promotes tissue repair in mice with oxygen-induced retinopathy of prematurity by promoting retinal stem cell proliferation and differentiation[J]. J Cell Physiol, 2019, 234(11): 21027-21038. DOI: 10.1002/jcp.28706.
52. 韓如意, 金子兵. 遺傳性眼底病基因和干細胞治療趨勢與面臨的挑戰和機遇[J]. 中華眼底病雜志, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.Han RY, Jin ZB. Progress and opportunities of gene and stem cell therapy on hereditary ocular fundus diseases[J]. Chin J Ocul Fundus Dis, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.
53. Xu Y, Lu X, Hu Y, et al. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice[J/OL]. J Pineal Res, 2018, 64(4): 12473[2018-03-08]. https://doi.org/10.1111/jpi.12473. DOI: 10.1111/jpi.12473.

Next Article
Clinical observations of micro-incision vitrectomy surgery for retinopathy of prematurity with early intervention failure

Chinese Journal of Ocular Fundus Diseases

Value the standardized treatment of pediatric retinal diseases to improve its treatment level

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content